BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 1886576)

  • 1. [Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer].
    Matsuda M; Shimizu Y; Chikamatsu E; Takayanagi K; Ishigure H; Murakami S; Odani K
    Nihon Geka Gakkai Zasshi; 1991 Jun; 92(6):716-21. PubMed ID: 1886576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
    Akdoğan M; Parlak E; Kayhan B; Balk M; Saydam G; Sahin B
    Turk J Gastroenterol; 2003 Sep; 14(3):181-4. PubMed ID: 14655062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
    Brockmann J; Emparan C; Hernandez CA; Sulkowski U; Dietl KH; Menzel J; Wolters H; Glodny B; Senninger N
    Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
    Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
    Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of non-invasive diagnostic tests in detecting cancer of the pancreas.
    Wang JY; Chen FZ; Yang YZ
    Chin Med J (Engl); 1990 Oct; 103(10):817-20. PubMed ID: 2125254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile cytology. Diagnostic role in the management of biliary obstruction.
    Nilsson B; Wee A; Yap I
    Acta Cytol; 1995; 39(4):746-52. PubMed ID: 7631549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of bile cytology in the diagnostic management of patients with biliary tract obstruction.
    Cobb CJ; Floyd WN
    Acta Cytol; 1985; 29(2):93-100. PubMed ID: 2984868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
    Robles-Diáz G; Aceves G; Galván E
    Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on the clinical usefulness of NCC-ST-439 in cases of digestive tract cancer].
    Anzai K; Kurihara M; Izumi T
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1437-47. PubMed ID: 2212836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoembryonic antigen in the bile in patients with pancreatic and biliary cancer. Correlation with cytology and percutaneous transhepatic cholangiography.
    Tatsuta M; Yamamura H; Yamamoto R; Morii T; Okuda S; Tamura H
    Cancer; 1982 Dec; 50(12):2903-9. PubMed ID: 7139579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
    Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
    Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
    Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor markers in hepatoma, gallbladder-biliary tract and pancreas cancer].
    Nakahara M; Fujisawa K
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3010-9. PubMed ID: 2445292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoembryonic antigen messenger RNA expression using nested reverse transcription-PCR in the peripheral blood during follow-up period of patients who underwent curative surgery for biliary-pancreatic cancer: longitudinal analyses.
    Mataki Y; Takao S; Maemura K; Mori S; Shinchi H; Natsugoe S; Aikou T
    Clin Cancer Res; 2004 Jun; 10(11):3807-14. PubMed ID: 15173089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunohistochemical study of cancer-associated carbohydrate antigens in carcinoma of the biliary tract].
    Sasaki R
    Nihon Geka Gakkai Zasshi; 1989 Dec; 90(12):1976-88. PubMed ID: 2560529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.